FIGURE 8.

Irigenin inhibited tumorigenesis of GBM in vivo. (A) Bioluminescent imaging of disseminated C6-Luc orthotopic xenograft mice at different time points posttreatment with IR and the control group. (B) Fold change in the average radiance per mouse after normalization to the day 0 tumor burden as determined by bioluminescent imaging (n = 7 mice, per group). (C) Fold change in the average radiance per mouse at the experimental endpoint (day 19) for each treatment group (n = 7 mice, per group). (D) The body weight of the tumor-bearing mice was monitored every day (n = 5 mice, per group). (E) DAB staining of YAP, β-catenin and cleaved-Caspase 3 in GBM tumor of xenograft mice. Data were shown as mean ± SEM. ^* p < 0.05, ^** p < 0.01, compared with control treatment.